Summary of Key Points from the Conference Call Company Overview - The report focuses on Microchip Biotech, a company in the pharmaceutical industry, specifically analyzing its performance in 2025 and projections for 2026 [1] Financial Performance - In 2025, the company achieved a revenue of 910 million yuan, representing a year-over-year increase of 38% [1] - The revenue from the drug Sidabamine grew by 16% and it was included in the regular medical insurance directory [1] - The revenue from the drug Siglethana increased by 123%, indicating rapid growth for both products [1] - The net profit attributable to the parent company for 2025 was 53 million yuan, with a non-recurring profit of 38 million yuan, significantly improving from a net loss of 115 million yuan and a non-recurring loss of 205 million yuan in 2024 [1] - In Q4 2025, the company reported revenue of approximately 236 million yuan, a year-over-year increase of 33%, although there was a slight quarter-over-quarter decline due to price adjustments following the inclusion of Sidabamine in medical insurance [1] - The net profit attributable to the parent company in Q4 2025 was approximately -18 million yuan, with a non-recurring net profit of about -20 million yuan, both showing significant reduction in losses compared to previous periods [1] Future Projections - For 2026, the company anticipates continued data readouts, with key clinical results expected for several drugs [2] - The clinical results for Sidabamine in CRC Phase III are expected to be available by the end of 2026 to early 2027 [2] - The clinical results for Seoroni in PDAC Phase II are expected to mature by mid-2026 [2] - Additionally, preliminary human exploration results for oral PDL1 small molecules, TYK2 inhibitors, and next-generation AURORAB inhibitors are anticipated in the second half of 2026 [2] Additional Insights - The inclusion of Sidabamine in the medical insurance directory is a significant milestone that may enhance its market penetration and revenue potential [1] - The rapid growth rates of both Sidabamine and Siglethana suggest a strong demand and effective market strategies [1] - The company’s ability to reduce losses significantly indicates improving operational efficiency and potential for future profitability [1][2]